Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

Published:2017-08 Issue:8 Volume:4 Page:595-604
ISSN:2215-0366
Container-title:The Lancet Psychiatry
language:en
Short-container-title:The Lancet Psychiatry

Author:

Anderson Karen E,Stamler David,Davis Mat D,Factor Stewart A,Hauser Robert A,Isojärvi Jouko,Jarskog L Fredrik,Jimenez-Shahed Joohi,Kumar Rajeev,McEvoy Joseph P,Ochudlo Stanislaw,Ondo William G,Fernandez Hubert H

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference28 articles.

1. Tardive dyskinesia syndromes: current concepts;Aquino;Parkinsonism Relat Disord,2014

2. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs;Tarsy,2011

3. Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study;Woods;J Clin Psychiatry,2010

4. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies;Correll;Am J Psychiatry,2004

5. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis;Carbon;J Clin Psychiatry,2017

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid (Deuterio)difluoromethylation of Heteroatoms Using R‐22 Gas: A Demonstration of Flow Chemistry in Suppressing Intrinsic Reaction Pathways;Advanced Synthesis & Catalysis;2024-09-12

2. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease;Expert Review of Neurotherapeutics;2024-07-09

3. Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis;European Journal of Clinical Pharmacology;2024-07-06

4. Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use;Journal of Clinical Psychopharmacology;2024-06-21

5. Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review;Drug Safety;2024-06-11